West Pharmaceutical Services stock reports strong Q2 growth ahead of results ?????????? no
Published on 10/04/2026 at 23:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
West Pharmaceutical Services stock (ISIN US9553061055) was last at USD 364.98 on the NYSE on October 2, 2026 at 4:00 p.m. ET, with a daily change of -0.01 percent. The company enters its next reporting date after a second quarter in which revenue rose 13.8 percent year over year to USD 872.3 million, according to MarketBeat on September 25, 2026.
Q2 earnings beat expectations
West Pharmaceutical Services reported Q2 2026 EPS of USD 2.37, exceeding the USD 2.08 consensus estimate by USD 0.29. The result also stood above the USD 1.84 EPS reported for the same quarter a year earlier, giving the latest earnings comparison a clear year-over-year profit benchmark.
Revenue of USD 872.3 million surpassed the USD 839.98 million analyst estimate, while the company set Q3 2026 EPS guidance at USD 2.140-2.240. MarketBeat also reported full-year 2026 EPS guidance of USD 8.850-9.050.
Analysts keep a Moderate Buy view
The analyst consensus is Moderate Buy, based on 14 brokerages, with an average 12-month price target of USD 382.00. The published target range extends from USD 295.00 to USD 447.00, placing the current consensus above the October 2 trading level.
Recent analyst action has also leaned constructive. MarketScreener reported on September 22, 2026 that Morgan Stanley upgraded West Pharmaceutical Services to Overweight from Equalweight and raised its price target from USD 365 to USD 400.
October 22 results set the next test
West Pharmaceutical Services develops packaging, containment systems and delivery devices for injectable medicines. Its product range includes elastomer closures, syringe and cartridge components, vial seals and specialized drug delivery systems, according to the company website.
The next test arrives on October 22, 2026, when West Pharmaceutical Services is scheduled to report Q3 results before the market opens. The published consensus calls for EPS of USD 2.19 and revenue of USD 826.0 million for that quarter, according to MarketBeat.
Stock remains below its yearly high
West Pharmaceutical Services had a 52-week range of USD 199.89 to USD 386.00 and a market capitalization of USD 25.7 billion on October 2, 2026. Trading volume was 472,117 shares, leaving the stock USD 21.02 below its 52-week high.
West Pharmaceutical Services stock at a glance
- Company: West Pharmaceutical Services, Inc.
- ISIN: US9553061055
- Ticker: WST
- Trading venue: NYSE
- Price (as of October 2, 2026, 4:00 p.m. ET): USD 364.98
- Market capitalization: USD 25.7 billion (as of October 2, 2026)
- 52-week range: USD 199.89-386.00 (as of October 2, 2026)
- Sector / Industry: Healthcare / Medical Instruments and Supplies
- Index membership: S&P 500
Upcoming dates for West Pharmaceutical Services stock
- October 22, 2026: Q3 2026 earnings release before the market opens
More news and analyses on West Pharmaceutical Services stock
